ModifiedCentenePolicy CP.PHAR.98

Ruxolitinib (Jakafi, Opzelura) coverage

Medical necessity and prior authorization criteria for oral (Jakafi) and topical (Opzelura) ruxolitinib formulations for specified hematology/oncology and dermatology indications for Centene-affiliated health plans.

Policy Summary

PayerCentene

PolicyRuxolitinib (Jakafi, Opzelura) coverage

Policy CodePolicy CP.PHAR.98

Change TypeMultiple material updates (dosing, durations, indications)

Effective DateMar 1, 2012

Next Review Date

Key ActionSubmit prior authorization with indication-specific documentation including recent platelet count for myelofibrosis and BSA/age for topical Opzelura.

SourceLink

POLICY UPDATE CHANGES

Revised maximum dose of Opzelura from 60 g per month to 60 g per week per PI.

Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.

For myelofibrosis, added criterion for recent documentation of a platelet count of 6 50 d7 10^9/L per PI.

For AD and NSV, added that Opzelura is not prescribed concurrently with biologic medications (e.g., Dupixent, Adbry) per FDA labeling.

For GVHD, revised tablet quantity limit to 2 due to twice daily regimen.

Extended initial and continued approval duration from 6 to 12 months for several chronic oncology indications in Medicaid/HIM.

For PV, added option to be prescribed as initial treatment for high-risk PV.

Added off-label indications: immune-checkpoint-inhibitor-associated concomitant myositis/myocarditis and T-cell lymphoma per NCCN.

Added management options for immune effector cell 6parkinsonism and HLH-like syndrome among immunotherapy-related toxicities.

Added step therapy bypass for IL HIM per IL HB 5395.

For AD, updated criteria with pediatric extension to include ages 2 years and older per PI.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial Therapy: Myelofibrosis

Initial Approval Criteria - Myelofibrosis (ALL must be met):

MF Initial: 1. Diagnosis of myelofibrosis (primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF); 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Documentation of a recent (within the last 30 days) platelet count ≥ 50 × 10^9/L; 6. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 7. Request does not exceed health plan–approved quantity limit, if applicable; 8. Request meets one of the following: (a) dose does not exceed both (i) 50 mg per day and (ii) 2 tablets per day; OR (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence); 9. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

Initial Therapy: Polycythemia Vera

Initial Approval Criteria - Polycythemia Vera (ALL must be met):

PV Initial: 1. Diagnosis of polycythemia vera (PV); 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. One of the following: (a) prescribed as initial treatment for high‑risk PV; OR (b) failure of hydroxyurea, peginterferon, or interferon unless contraindicated or adverse effects preclude use; 7. Request does not exceed health plan–approved quantity limit, if applicable; 8. Request meets one of the following: (a) dose does not exceed both (i) 50 mg per day and (ii) 2 tablets per day; OR (b) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); 9. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Prior authorization may be required for hydroxyurea, peginterferon, or interferon; Approval duration per policy.

Initial Therapy: Graft‑Versus‑Host Disease

Initial Approval Criteria - Graft‑Versus‑Host Disease (ALL must be met):

GVHD Initial: 1. Diagnosis of steroid‑refractory acute or chronic graft‑versus‑host disease (GVHD) following hematopoietic cell transplantation; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with an oncologist, hematologist, or bone marrow transplant specialist; 4. Age ≥ 12 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. For acute GVHD: failure of a systemic corticosteroid as defined in Appendix D unless contraindicated or clinically significant adverse effects are experienced; 7. For chronic GVHD: either failure of a systemic corticosteroid at up to maximally indicated doses OR failure of a systemic immunosuppressant at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced; 8. Jakafi is not prescribed concurrently with Imbruvica or Rezurock; 9. Request does not exceed health plan–approved quantity limit, if applicable; 10. Request meets one of the following: (a) dose does not exceed both (i) 20 mg per day and (ii) 2 tablets per day; OR (b) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); 11. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less. Steroid‑refractoriness defined per Appendix D.

Initial Therapy: Chronic Myelomonocytic Leukemia / MDS/MPN (Off-label)

Initial Approval Criteria - Chronic Myelomonocytic Leukemia / MDS/MPN (off-label; ALL must be met):

MDS/MPN Off-label: 1. Diagnosis of chronic myelomonocytic leukemia OR MDS/MPN; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. Request does not exceed health plan–approved quantity limit, if applicable; 7. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence); 8. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

Initial Therapy: Pediatric Ph-like B-ALL (Off-label)

Initial Approval Criteria - Pediatric Ph‑like B-ALL (off‑label; ALL must be met):

Pediatric Ph-like B-ALL: 1. Diagnosis of pediatric 'Ph‑like' B‑cell acute lymphoblastic leukemia; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age < 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. Prescribed in combination with an induction or consolidation regimen; 7. Tumor is positive for a JAK‑STAT pathway mutation, JAK2 fusion, EPOR rearrangement, SH2B3 alteration, or IL7R insertion/deletion; 8. Request does not exceed health plan–approved quantity limit, if applicable; 9. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); 10. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

Initial Therapy: Myeloid/Lymphoid Neoplasm with Eosinophilia (Off-label)

Initial Approval Criteria - Myeloid/Lymphoid Neoplasm with Eosinophilia (off‑label; ALL must be met):

Neoplasm with Eosinophilia: 1. Diagnosis of a lymphoid, myeloid, or mixed‑lineage neoplasm with eosinophilia; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. Positive for a JAK2 mutation; 7. Request does not exceed health plan–approved quantity limit, if applicable; 8. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence); 9. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

Initial Therapy: Essential Thrombocythemia (Off-label)

Initial Approval Criteria - Essential Thrombocythemia (off‑label; ALL must be met):

Essential Thrombocythemia: 1. Diagnosis of essential thrombocythemia; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. Failure of hydroxyurea, peginterferon, interferon, or anagrelide unless contraindicated or clinically significant adverse effects are experienced (prior authorization may be required for these agents); 7. Request does not exceed health plan–approved quantity limit, if applicable; 8. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence); 9. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

General Jakafi initial criteria

Covered when ALL of the following are met for Jakafi (general initial requirements):

General Jakafi requirements: 1. Request is for Jakafi (oral ruxolitinib); 2. Prescribed by or in consultation with a hematologist or oncologist; 3. Age ≥ 18 years (unless indication specifies otherwise); 4. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 5. Failure of hydroxyurea, peginterferon, interferon, or anagrelide where applicable unless contraindicated or adverse effects preclude use; 6. Request does not exceed health plan–approved quantity limit, if applicable; 7. Dose is within FDA maximum limit or is supported by practice guidelines or peer‑reviewed literature for the requested use (prescriber must submit supporting evidence); 8. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Reflects general requirements across Jakafi oncology indications; prior authorization required.

T-cell lymphoma (off-label)

T‑Cell Lymphomas (off‑label) — Covered when ALL of the following are met:

T-cell lymphoma criteria: 1. Diagnosis of T‑cell lymphoma; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. Prescribed for palliative therapy OR has received ≥ 1 prior line of systemic therapy; 7. Request does not exceed health plan–approved quantity limit, if applicable; 8. Dose is within FDA maximum limit or is supported by practice guidelines or peer‑reviewed literature for the off‑label use (prescriber must submit supporting evidence); 9. Prescribed regimen must be FDA‑approved or recommended by NCCN.

Off‑label but allowable with required documentation and evidence.

Atopic Dermatitis (Opzelura) initial

Atopic Dermatitis (Opzelura) — Covered when ALL of the following are met:

Atopic Dermatitis initial: 1. Diagnosis of atopic dermatitis (AD); 2. Body surface area (BSA) involvement ≤ 20%; 3. Request is for Opzelura (topical ruxolitinib 1.5% cream); 4. Age ≥ 2 years; 5. Prescribed by or in consultation with a dermatologist or allergist; 6. Member is not immunocompromised; 7. Either: (a) failure of two formulary medium‑to‑very high potency topical corticosteroids each used ≥ 2 weeks unless contraindicated; OR (b) use is for face or intertriginous areas (bypass to step therapy); 8. Failure of a topical calcineurin inhibitor used ≥ 4 weeks unless contraindicated; 9. Failure of Eucrisa used ≥ 4 weeks unless contraindicated; 10. Opzelura is not prescribed concurrently with biologic medications (e.g., Dupixent, Adbry), other JAK inhibitors, or potent immunosuppressants (e.g., azathioprine, cyclosporine); 11. Dose does not exceed age‑specific limits (see dosing node).BSA ≤ 20%

Step therapy requirements apply; IL HIM exemption noted per IL HB 5395.

Opzelura dosing limits: Age 2 to <12 years: one 60‑gram tube per 2 weeks; Age ≥ 12 years: one 60‑gram tube per week OR one 100‑gram tube per 2 weeks.60 g/week (age ≥12) or 60 g/2 weeks (age 2‑<12)

Per product labeling and policy updates; approval durations differ by scenario.

Nonsegmental vitiligo (Opzelura) initial

Nonsegmental Vitiligo (Opzelura) — Covered when ALL of the following are met:

NSV initial: 1. Diagnosis of nonsegmental vitiligo (NSV); 2. Documentation total vitiligo involvement ≤ 10% BSA; 3. Request is for Opzelura (topical ruxolitinib 1.5% cream); 4. Prescribed by or in consultation with a dermatologist or allergist; 5. Age ≥ 12 years; 6. Either: (a) two formulary medium‑to‑very high potency topical corticosteroids in the previous 6 months unless contraindicated; OR (b) use is for face or intertriginous areas (bypass to step therapy); 7. Failure of a topical calcineurin inhibitor used ≥ 4 weeks unless contraindicated; 8. Opzelura is not prescribed concurrently with biologic medications, other JAK inhibitors, or potent immunosuppressants; 9. Dose does not exceed age‑specific limits for age ≥ 12 (one 60‑gram tube per week OR one 100‑gram tube per 2 weeks).NSV ≤ 10% BSA

Approval duration: initial duration per policy (see continuation criteria); IL HIM exemption applies for step therapy.

Immunotherapy-related toxicities (off-label)

Immunotherapy‑Related Toxicities (off‑label) — Covered when ALL of the following are met:

Immunotherapy-related toxicities: 1. One of the following: (a) CAR T‑cell therapy associated grade 4 cytokine release syndrome (CRS); (b) management of immune effector cell (IEC)‑parkinsonism related to BCMA‑directed CAR T‑cell therapy; (c) one of the following immune‑checkpoint‑inhibitor toxicities: (i) management of concomitant myositis and myocarditis in combination with abatacept; OR (ii) hemophagocytic lymphohistiocytosis (HLH)‑like syndrome; 2. Request is for Jakafi (oral ruxolitinib); 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age ≥ 18 years; 5. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 6. For CAR T‑cell associated CRS: failure of both high‑dose systemic corticosteroids and anti‑IL‑6 therapy unless contraindicated; 7. For HLH syndrome: failure or lack of response to corticosteroids; 8. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); 9. Request does not exceed health plan–approved quantity limit, if applicable.

Approval durations vary by toxicity: HLH up to 2 total doses; CRS 1 month; myositis/myocarditis 2 months; IEC‑parkinsonism 12 months.

Continuation criteria

Continued therapy — Covered when ALL of the following are met:

Continuation for AD/NSV: 1. Member is currently receiving Opzelura via the Centene benefit or previously met initial approval (continuity of care may apply); 2. Member is responding positively to therapy (e.g., reduced symptoms or lesion improvement documented); 3. Request is for Opzelura; 4. Opzelura is not prescribed concurrently with biologic medications, other JAK inhibitors, or potent immunosuppressants; 5. Dose increases must not exceed specified age‑based limits per product labeling.

Approval duration: 12 months.

Continuation for Jakafi (other indications): 1. Member is currently receiving Jakafi via the Centene benefit or documentation supports member has been receiving Jakafi for at least 30 days for a covered indication; 2. Member is responding positively to therapy; 3. Request is for Jakafi; 4. Member must use ruxolitinib formulation if available unless contraindicated or clinically significant adverse effects are experienced; 5. For GVHD, Jakafi is not prescribed concurrently with Imbruvica or Rezurock; 6. Request does not exceed health plan–approved quantity limit, if applicable; 7. If request is for a dose increase, the new dose must meet one of the following: (a) for MF/PV: new dose does not exceed 50 mg (2 tablets) per day; (b) for acute GVHD/cGVHD: new dose does not exceed 20 mg (2 tablets) per day; (c) new dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

Other/Unlisted indications

Other diagnoses/indications — Process when indication not specifically listed:

Other/Unlisted uses: 1. If the drug label has changed within the last 6 months and the change is not reflected in this policy, refer to the appropriate formulary/no‑coverage or non‑formulary policy for the applicable line of business; OR 2. If requested use (diagnosis, age, dosing) is not specifically listed in this policy and criterion 1 does not apply, refer to the off‑label use policy for the relevant line of business (policy numbers provided).

Provider must supply sufficient supporting documentation per off‑label use policies.

Indication-specific dosing and coverage

Covered when ALL of the following dosing/indication‑specific conditions are met:

Myelofibrosis (dosing): Ruxolitinib (Jakafi) starting dose based on baseline platelet count: >200 × 10^9/L = 20 mg PO BID; 100–200 × 10^9/L = 15 mg PO BID; 50–<100 × 10^9/L = 5 mg PO BID. Range 5–25 mg PO BID; maximum 50 mg/day.platelet-based dosing tiers

Support: dosing table and product labeling; children: see indication specifics.

Polycythemia Vera (dosing): Ruxolitinib (Jakafi) starting dose for PV: 10 mg PO BID; range 5–25 mg PO BID; maximum 50 mg/day.starting dose 10 mg BID

Support: dosing table and product labeling.

Acute GVHD (dosing): Ruxolitinib (Jakafi) starting dose for acute GVHD: 5 mg PO BID; range 5–10 mg PO BID; maximum 20 mg/day. Approval should align with NCCN definitions of steroid‑refractory/resistant disease.

Updated coverage criteria (summary of changes)

Coverage updated for multiple indications with specified limits and durations (summary of recent changes):

Opzelura topical dosing update: Maximum topical dose per product labeling revised to 60 g per week (with allowance for one 100‑g tube per 2 weeks per PI in some scenarios).60 g/week

Operational dosing limit change aligned to product labeling.

Concurrent therapy restriction for Opzelura: Opzelura is not prescribed concurrently with biologic medications (e.g., Dupixent, Adbry) for AD and NSV in initial and continued therapy sections per FDA labeling.

Added to initial and continued therapy sections.

Myelofibrosis safety lab requirement: For myelofibrosis, recent documentation of platelet count ≥ 50 × 10^9/L is required per product labeling.≥ 50 × 10^9/L

Opzelura should not be used in combination with systemic immunomodulatory therapies. Per the product labeling, use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants (e.g., azathioprine, cyclosporine) is not recommended. Requests that propose concomitant use with these agents should be evaluated for safety concerns and will not meet combination-use criteria in this policy.

This policy only authorizes coverage for FDA‑approved indications and those off‑label uses explicitly addressed in the document. Non‑FDA approved indications not listed in this policy are excluded unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy for the member's line of business (see referenced off‑label policies).

Opzelura carries boxed warnings that must be considered when assessing appropriateness. The boxed warnings include risks of serious infections, increased mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. These warnings note occurrences of opportunistic infections (including tuberculosis and invasive fungal infections), higher rates of all‑cause mortality, observed lymphomas and other malignancies, increased rates of MACE (including myocardial infarction and stroke), and thrombotic events (including DVT and PE).

Per updated FDA labeling incorporated into this policy, Opzelura must not be prescribed concurrently with biologic medications (e.g., Dupixent, Adbry) for atopic dermatitis and nonsegmental vitiligo. Concurrent prescribing with those biologics is explicitly disallowed in both initial and continuation authorizations.

Off‑label uses that are not specifically addressed within this policy are not authorized unless the prescriber submits sufficient supporting evidence of safety and efficacy per the appropriate off‑label use policy. In the absence of such documentation, requests for indications outside this policy will be denied.

Certain patient safety factors may render topical JAK inhibitor therapy inappropriate. Because Opzelura's boxed warnings include serious infections, mortality, malignancy, MACE, and thrombosis, providers should refrain from prescribing topical therapy for patients at high risk for these events unless there is clear justification and documentation supporting safe use. Clinical justification should be included with the prior authorization request when such risks are present.

Quantity limits established by the product labeling and this policy are enforced. For Opzelura, the maximum topical dose was revised per the prescribing information to 60 g per week (with limited allowance for a single 100‑g tube per 2 weeks in certain situations per PI); requests exceeding plan‑approved quantity limits for either Jakafi or Opzelura are subject to denial if not justified with supporting clinical documentation.

Coding, Billing, and Dispensing Information

Prior Authorization Steps and Required Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization Required — Jakafi and Opzelura require prior authorization. Approval is contingent on meeting the indication‑specific criteria in this policy and adherence to plan quantity limits and approval durations.

PA required for Jakafi and Opzelura for all listed indications
Ensure requested dose/regimen falls within FDA labeling or is supported by guidelines/peer‑reviewed literature with submitted evidence

Documentation Required

Required Clinical Documentation

Documentation Requirement — Provider must submit supporting clinical documentation with the PA request. Failure to provide required documentation may result in denial.

Include office chart notes and relevant clinical progress notes
Include laboratory results (e.g., recent platelet count for myelofibrosis within 30 days)

Allowed Regimens, Dosing Limits, and Approval Durations

Indication / Context	Dosing constraints / maximums
Myelofibrosis (MF)
Dose must not exceed 50 mg per day and 2 tablets per day unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence). Recent platelet count ≥ 50 × 10^9/L required per product labeling.
Polycythemia vera (PV)
Dose must not exceed 50 mg per day and 2 tablets per day unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence). PV may be prescribed as initial treatment for high‑risk PV per update.
Acute graft‑versus‑host disease (acute GVHD)
Dose must not exceed 20 mg per day and 2 tablets per day unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence). Align approval with NCCN definitions of steroid‑refractory/resistant disease.
Chronic graft‑versus‑host disease (cGVHD)
Dose must not exceed 20 mg per day and 2 tablets per day unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence). Align approval with NCCN definitions of steroid‑refractory/resistant disease.
Off‑label hematologic malignancies and other listed indications (e.g., MDS/MPN, CMML, pediatric Ph‑like B‑ALL, essential thrombocythemia, T‑cell lymphomas)
Dose must be within FDA maximum limits for any FDA‑approved indication (commonly 50 mg/day maximum for oral Jakafi) or supported by practice guidelines/peer‑reviewed literature with prescriber evidence submission.
Topical ruxolitinib (Opzelura) — Atopic dermatitis and nonsegmental vitiligo
Apply thinly twice daily to affected areas with BSA limits (AD ≤20% BSA; NSV ≤10% BSA) and maximum topical dosing per product labeling: age ≥12 years options include 60 g/week or 100 g/2 weeks; ages 2 to <12 years: 60 g/2 weeks. (PI revised maximum to 60 g/week noted in updates.)

Operational rule	Limit
Dose increase limit for new or escalated Jakafi dose in Myelofibrosis (MF)
New dose must not exceed 50 mg per day (equivalent to 2 tablets per day) when increasing dose; any increase beyond this requires supporting guidelines or peer‑reviewed literature and prescriber evidence.

Operational rule	Limit
Dose increase limit for new or escalated Jakafi dose in acute or chronic GVHD
New dose must not exceed 20 mg per day (equivalent to 2 tablets per day); any increase beyond this requires supporting guidelines or peer‑reviewed literature and prescriber evidence.

Immunotherapy‑related toxicity	Approval duration / notes
Hemophagocytic lymphohistiocytosis (HLH)‑like syndrome
Approval duration: up to 2 total doses.
Cytokine release syndrome (CRS) related to CAR T‑cell therapy
Approval duration: 1 month; use contingent on failure of high‑dose systemic corticosteroids and anti‑IL‑6 therapy unless contraindicated.
Concomitant myositis and myocarditis associated with immune‑checkpoint inhibitors
Approval duration: 2 months.
Immune effector cell–associated parkinsonism (IEC‑parkinsonism)
Approval duration: 12 months; added as a management option per recent updates.

Therapeutic alternative / regimen	Context / examples listed in policy
CHOP / CHOEP / EPOCH / ICE / HyperCVAD and other multi‑agent chemotherapy regimens
Listed as examples of chemotherapy regimens used in hematologic malignancies; provided as therapeutic context when considering use of ruxolitinib relative to other systemic therapies.
Brentuximab vedotin (Adcentris) + CHP, gemcitabine‑based regimens, platinum combinations
Included among alternative systemic options that may be considered prior to or in conjunction with ruxolitinib depending on indication and line of therapy.
Hypomethylating agents and targeted agents (azacitidine, ibrutinib, imatinib, duvelisib, pralatrexate, romidepsin, lenalidomide)
Listed as therapeutic alternatives or adjunctive regimens in appendices; may inform prior‑therapy requirements or sequencing decisions for off‑label uses.

Context / Indication	Quantity / dispense rule
Graft‑versus‑host disease (GVHD) — oral Jakafi tablets for acute or chronic GVHD
Tablet quantity limit revised to 2 per dispense to align with twice‑daily (BID) regimens; requests must not exceed health plan‑approved quantity limits.

Management option / toxicity	Specified duration / usage guidance
Immune effector cell–associated parkinsonism (IEC‑parkinsonism)
Added as a management option for immunotherapy‑related toxicities; approval duration up to 12 months per policy update.
HLH‑like syndrome associated with immunotherapy
Approved as a management option with dosing and use limited to up to 2 total doses (short course), per policy guidance.

Update / Indication	Coverage effect
Polycythemia vera (PV) — high‑risk patients
Policy updated to allow Jakafi as an initial treatment option for high‑risk PV in addition to use after failure of hydroxyurea or interferons, per recent changes noted in the policy update.

Line of Therapy Designations

first-line | second-line

Line‑of‑therapy designations (where specified):

PV line: Prescribed as initial treatment for high‑risk PV OR for patients who have failed hydroxyurea/peginterferon/interferon.

combination with induction/consolidation

When required by indication:

Pediatric B-ALL combination: Must be prescribed in combination with an induction or consolidation regimen for pediatric Ph‑like B‑ALL.

second-line | palliative

Designations for T‑cell lymphoma:

Biomarker and Laboratory Requirements

inv-62: JAK-STAT pathway mutation / JAK2 mutation — biomarker requirement entries where applicable

Pediatric Ph-like B-ALL biomarker requirementPositive for a JAK-STAT pathway mutation, JAK2 fusion, EPOR rearrangement, SH2B3 alteration, or IL7R insertion/deletion is required

Myeloid/lymphoid neoplasm with eosinophiliaRequires positive JAK2 mutation for coverage (off-label) when criteria met

Evidence submissionPrescriber must document molecular testing results as part of prior authorization

Documentation Required

Operational requirement: recent platelet count ≥ 50 × 10^9/L for MF

For myelofibrosis PA requests, include recent documentation of platelet count ≥ 50 × 10^9/L per the product labeling as an operational lab requirement on the prior authorization submission.

Platelet count must be recent (within last 30 days) and ≥ 50 × 10^9/L

Definitions and Abbreviations

inv-48: Ruxolitinib formulations — define Jakafi (oral) and Opzelura (topical)

Jakafi (oral formulation)Jakafi refers to oral ruxolitinib tablets used for hematologic indications (MF, PV) and GVHD; available as 5, 10, 15, 20, 25 mg tablets

Opzelura (topical formulation)Opzelura refers to topical ruxolitinib cream 1.5% indicated for atopic dermatitis and nonsegmental vitiligo

Distinct usesJakafi and Opzelura are different formulations with indication- and dosing-specific rules in policy

inv-49: Opzelura limitations — combination limitations and contraindicated concurrent agents

Combination limitationsOpzelura should not be used concurrently with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants (e.g., azathioprine, cyclosporine); policy and PI note this limitation

Concurrent biologics restriction

Background and Clinical Context

Ruxolitinib is a Janus kinase (JAK) inhibitor available in oral and topical formulations. The oral formulation (Jakafi) is indicated for hematologic conditions including myelofibrosis, polycythemia vera, and steroid‑refractory graft‑versus‑host disease, with dosing tiers and maximum daily doses determined by indication and baseline labs (e.g., platelet‑based starting doses for myelofibrosis). The topical formulation (Opzelura) is a 1.5% cream indicated for atopic dermatitis and nonsegmental vitiligo in specified age groups and body surface area limits; its product labeling and this policy define the applicable dosing, age, and BSA thresholds.

Policy Summary

PayerCentene

PolicyRuxolitinib (Jakafi, Opzelura) coverage

Policy CodePolicy CP.PHAR.98

Change TypeMultiple material updates (dosing, durations, indications)

Effective DateMar 1, 2012

Next Review Date

Key ActionSubmit prior authorization with indication-specific documentation including recent platelet count for myelofibrosis and BSA/age for topical Opzelura.

SourceLink

On This Page

Step Therapy

Step Therapy / Prior Treatment Requirements

Step Therapy and Prior Treatment Requirements — Many Jakafi and Opzelura indications require prior trials or failures of specified therapies unless contraindicated or adverse effects occur.

For MF, PV, GVHD and certain off‑label hematologic indications: trial/failure of alternatives (e.g., ruxolitinib when available; hydroxyurea, peginterferon, interferon, anagrelide where specified) is required unless contraindicated
For GVHD: failure of systemic corticosteroids for acute GVHD per NCCN timing/definitions (see Appendix D) and for chronic GVHD failure of systemic corticosteroid or systemic immunosuppressant as specified
For pediatric Ph‑like B‑ALL and other off‑label uses: required prior/concomitant regimens per criteria

Step Therapy

Step Therapy for Opzelura

Opzelura Specific Step Therapy — Prior to approval for atopic dermatitis and nonsegmental vitiligo, providers must document failure of required topical therapies unless contraindicated. Illinois HIM requests are exempt from these step requirements per IL HB 5395 (effective 1/1/2026).

Failure of two formulary medium‑to‑very high potency topical corticosteroids (each ≥ 2 weeks) or use for face/intertriginous areas exception
Failure of a topical calcineurin inhibitor used ≥ 4 weeks
Failure of Eucrisa® (crisaborole) used ≥ 4 weeks
IL HIM statutory bypass: step therapy requirements do not apply for Illinois HIM requests as of 1/1/2026 per IL HB 5395

Billing Rule

Requests Exceeding Health Plan‑Approved Quantity Limits

Quantity Limits and Approval Durations — Requests must not exceed health plan‑approved quantity limits; exceeding plan limits may result in denial. Approval durations vary by line of business and indication.

Include the specific indication and requested quantity on the PA submission
Jakafi: follow indication‑specific tablet/day limits (e.g., MF/PV max 50 mg/day; GVHD max 20 mg/day) and plan quantity limits
Opzelura: follow topical maximums (age ≥ 12 years: 60 g/week or 100 g/2 weeks; age 2–<12 years: 60 g/2 weeks)
Approval durations: Medicaid/HIM typically 12 months for chronic oncology indications; Commercial 12 months or duration of request (whichever is less); Opzelura AD initial approval = 8 weeks

Documentation Required

GVHD Steroid Refractoriness Documentation

GVHD Steroid Refractoriness Documentation — For acute and chronic GVHD, documentation must meet NCCN definitions for steroid‑refractory or steroid‑resistant disease (timing and dose thresholds) to support Jakafi use.

Acute GVHD: progression within 35 days on ≥ 2 mg/kg/day prednisone equivalent, or failure to improve within 5–7 days, or incomplete response after >28 days of immunosuppressive treatment
Chronic GVHD: progression while on prednisone ≥ 1 mg/kg/day for 1–2 weeks, or stable disease while on ≥ 0.5 mg/kg/day (or 1 mg/kg every other day) for 1–2 months

inv-53: Steroid-refractory or -resistant GVHD — definition per policy/NCCN

Acute GVHD steroid-refractory definitionAcute GVHD: progression within 35 days of therapy onset while on ≥2 mg/kg/day prednisone-equivalent, or failure to improve within 5–7 days, or incomplete response after >28 days of immunosuppressive treatment

Chronic GVHD steroid‑resistant definitionChronic GVHD: progression while on ≥1 mg/kg/day prednisone-equivalent for 1–2 weeks, or stable disease on ≥0.5 mg/kg/day (or 1 mg/kg every other day) for 1–2 months

Source guidanceDefinitions sourced from NCCN Hematopoietic Cell Transplantation: GVHD (Appendix D) referenced in policy

inv-55: Oral ruxolitinib tablets; subject to quantity limits and indication-specific durations (Jakafi)

Jakafi (oral) summaryOral ruxolitinib tablets (Jakafi) are subject to indication-specific maximum daily doses (e.g., MF/PV max 50 mg/day; acute/cGVHD max 20 mg/day) and plan quantity limits; prior authorization required

Quantity limits and fillsPolicy notes tablet quantity limit revised to 2 for GVHD reflecting BID regimen; requests exceeding health plan–approved quantity limits may be denied

Approval durationsJakafi approval durations vary by indication; continuation and initial approvals standardized to 12 months for many chronic oncology indications per recent updates